SEC Form 4 · accession 0001209191-15-056046
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ken Valenzano
Officer — SVP, Pharmacology & Biology
Period of report
Jun 22, 2015
Accepted (ET)
Jun 24, 2015 · 7:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Jun 22, 2015 | M | 20,500 | $13.8543 | A | 48,187 | D | |
| Common stockF3 | Jun 22, 2015 | S | 20,500 | $13.8543 | D | 27,687 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $4.16 | Jun 22, 2015 | M | 2,500 | D | Nov 1, 2013 | Nov 16, 2019 | Common Stock | 2,500 | 22,500 | D |
| Stock Options (right to buy) | $4.38 | Jun 22, 2015 | M | 3,000 | D | Jun 4, 2013 | Jun 4, 2022 | Common Stock | 3,000 | 27,000 | D |
| Stock Options (right to buy) | $3.53 | Jun 22, 2015 | M | 5,000 | D | Jan 28, 2014 | Jan 28, 2023 | Common Stock | 5,000 | 15,000 | D |
| Stock Options (right to buy) | $2.52 | Jun 22, 2015 | M | 5,000 | D | Jun 18, 2014 | Jun 18, 2023 | Common Stock | 5,000 | 21,500 | D |
| Stock Options (right to buy) | $2.45 | Jun 22, 2015 | M | 5,000 | D | Jan 3, 2015 | Jan 3, 2024 | Common Stock | 5,000 | 42,500 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2015.
- F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.60 to $14.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.60 to $14.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.